Human Clinical Trial Begins For Texas A&M-Discovered Drug To Treat Angelman Syndrome

Jun 2, 2025 • 6 min. read

Developed by biopharmaceutical company Ultragenyx, GTX-102 is the first clinically developed drug targeting the genetic causes of Angelman syndrome rather than symptoms.